Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9–14 in Kenya, Africa
| Autor: | Nelly Mugo, Anna Wald, Connie Celum, Ruanne V. Barnabas, Linda O. Eckert, Jared M. Baeten, Kenneth Ngure, Stephen Gakuo, Lydia Odero |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Adolescent 030231 tropical medicine HIV Infections Antibodies Viral 03 medical and health sciences 0302 clinical medicine Immune system Human Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18 Humans Medicine Papillomavirus Vaccines 030212 general & internal medicine Child General Veterinary General Immunology and Microbiology biology medicine.diagnostic_test business.industry Papillomavirus Infections Public Health Environmental and Occupational Health Antibody titer virus diseases Kenya Vaccination Titer Infectious Diseases Immunization Immunoassay Antibody Formation Immunology biology.protein Molecular Medicine Female Antibody business Viral load |
| Zdroj: | Vaccine. 39:4751-4758 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2020.12.020 |
| Popis: | OBJECTIVES HIV infected children remain at increased risk of HPV associated malignancies as they initiate sexual activity. Though they mount a vigorous immune response to the quadrivalent human papillomavirus (QHPV-6, -11,-16, and -18; Gardasil®) vaccine, durability of the immune response is uncertain. We assessed antibody responses to HPV 6, -11, -16 and -18 for up to 48 months following administration of quadrivalent human papillomavirus vaccine in HIV-infected girls and boys ages 9-14 years in Kenya. DESIGN Of 178 girls and boys who had previously received three doses of the quadrivalent HPV vaccine, 176 enrolled into extended follow up for 4 years. HPV antibodies to -6, -11, -16 and -18 were measured at 24, 36 and 48 months after the first vaccine dose using the total immunoglobulin G immunoassay (IgG LIA). We evaluated the magnitude and trend in HPV vaccine response and the effect of plasma HIV-1 RNA on HPV vaccine response from month 24 to month 48 of follow up. RESULTS At re-enrollment, 24 months after initial vaccination, median age of participants was 14 years (range 11-17); 167 (95%) were receiving antiretroviral therapy and 110 (66%) had plasma HIV RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect